Načítá se...
Type I interferon antagonists in clinical development for lupus
INTRODUCTION: Systemic lupus erythematosus (SLE) is a severe chronic and incurable autoimmune disease. Treatment includes glucocorticoids and small molecule immunosuppressants which typically result in partial responses, and hence there is a great need for new therapies. The type I interferon (IFN)...
Uloženo v:
| Vydáno v: | Expert Opin Investig Drugs |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7924012/ https://ncbi.nlm.nih.gov/pubmed/32700979 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2020.1797677 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|